Long-term outcomes of catheter ablation in atrial fibrillation patients: the impact of changed CHA2DS2-VASc scores
Introduction Catheter ablation is widely utilized for atrial fibrillation (AF) management, yet long-term recurrence remains challenging. It is critical to understand how cardiovascular comorbidities, as captured by the CHA 2 DS 2 -VASc score, affect AF recurrence and major adverse cardiovascular and cerebrovascular events (MACCE) after ablation. Methods This analysis used data from a prospectively maintained, single-center observational registry (ChiCTR-OCH-14004674) involving 1,685 patients who underwent AF catheter ablation between January 2015 and December 2019. The relationship between longitudinal (time-updated) CHA 2 DS 2 -VASc score changes and AF recurrence and MACCE was examined with time-to-event methods. Results Over the course of a 58.1 ± 17.1-month follow-up period, the CHA 2 DS 2 -VASc score rose from 1.84 ± 1.35 to 3.10 ± 1.44. AF recurrence was observed in 442 patients (26.2%). Patients with a changed CHA 2 DS 2 -VASc score demonstrated a higher incidence of AF recurrence (hazard ratio [HR] and 95% Confidence Interval [CI]: 1.552 (1.398–1.724), p < 0.001) and MACCE post-ablation (HR [95%CI]: 4.90 (3.21–7.50)). In a time-updated Cox model that used only information available before each event, this association persisted (AF recurrence HR [95% CI]: HR 4.98 (3.87–6.40) unadjusted; 5.48 (4.22–7.10) adjusted for age, sex and baseline CHA₂DS₂-VASc). Multivariable analyses identified an increasing CHA 2 DS 2 -VASc score, along with new-onset comorbidities such as diabetes, hypertension, and vascular disease, as significant predictors of AF recurrence. An increased CHA 2 DS 2 -VASc score was also markedly associated with the elevated MACCE risk. Notably, crossing an age threshold itself was not independently associated with recurrence; the prognostic signal was carried by incident non-age comorbidities rather than by aging per se. Discussion A changed CHA 2 DS 2 -VASc score serves as a dynamic and salient marker for AF recurrence and MACCE following AF ablation. Our findings highlight the importance of vigilant monitoring and management of cardiovascular risk factors in post-ablation patients.
Authors
- Bing Rong (ORCID: https://orcid.org/0009-0007-0815-7570)
- Kai Zhang (ORCID: https://orcid.org/0000-0003-4213-7745)
- Mei Li (ORCID: https://orcid.org/0000-0001-7270-4902)
- Xinyan Yang (ORCID: https://orcid.org/0009-0000-2887-2087)
- Wenqiang Han
- Mingjie Lin
- Jingquan Zhong
- Juntao Wang
- Tongshuai Chen
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Shandong University (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Cardiovascular Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.3389/fcvm.2026.1949346
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China